首页> 美国卫生研究院文献>Journal of Clinical Medicine >Recent Advances and Clinical Outcomes of Kidney Transplantation
【2h】

Recent Advances and Clinical Outcomes of Kidney Transplantation

机译:肾脏移植的最新进展和临床结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent advances in surgical, immunosuppressive and monitoring protocols have led to the significant improvement of overall one-year kidney allograft outcomes. Nonetheless, there has not been a significant change in long-term kidney allograft outcomes. In fact, chronic and acute antibody-mediated rejection (ABMR) and non-immunological complications following kidney transplantation, including multiple incidences of primary kidney disease, as well as complications such as cardiovascular diseases, infections, and malignancy are the major factors that have contributed to the failure of kidney allografts. The use of molecular techniques to enhance histological diagnostics and noninvasive surveillance are what the latest studies in the field of clinical kidney transplant seem to mainly focus upon. Increasingly innovative approaches are being used to discover immunosuppressive methods to overcome critical sensitization, prevent the development of anti-human leukocyte antigen (HLA) antibodies, treat chronic active ABMR, and reduce non-immunological complications following kidney transplantation, such as the recurrence of primary kidney disease and other complications, such as cardiovascular diseases, infections, and malignancy. In the present era of utilizing electronic health records (EHRs), it is strongly believed that big data and artificial intelligence will reshape the research done on kidney transplantation in the near future. In addition, the utilization of telemedicine is increasing, providing benefits such as reaching out to kidney transplant patients in remote areas and helping to make scarce healthcare resources more accessible for kidney transplantation. In this article, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.
机译:外科手术,免疫抑制和监测方案的最新进展已导致一年同种异体肾移植结果的显着改善。但是,长期移植肾的结局没有明显改变。实际上,肾脏移植后的慢性和急性抗体介导的排斥反应(ABMR)和非免疫并发症,包括多种原发性肾脏疾病的发病率,以及诸如心血管疾病,感染和恶性肿瘤等并发症,都是造成这种情况的主要因素肾移植失败。使用分子技术来增强组织学诊断和非侵入性监视是临床肾脏移植领域的最新研究似乎主要关注的领域。越来越多的创新方法被用于发现免疫抑制方法,以克服关键的致敏性,防止抗人白细胞抗原(HLA)抗体的产生,治疗慢性活性ABMR并减少肾脏移植后非免疫性并发症的发生,例如原发性复发肾脏疾病和其他并发症,例如心血管疾病,感染和恶性肿瘤。在当今利用电子健康记录(EHR)的时代,人们坚信大数据和人工智能将在不久的将来重塑有关肾脏移植的研究。此外,远程医疗的利用正在增加,其好处包括可以接触偏远地区的肾脏移植患者,并有助于使稀缺的医疗资源更易于用于肾脏移植。在本文中,我们讨论了可能会影响长期同种异体移植以及患者存活的肾脏移植的最新研究进展。还探讨了活体肾脏捐赠的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号